Stockscreener 앱 받기
0.5108
27.19%
0.1092
시장 영업 전:
.51
-0.0008
-0.16%
Neurosense Therapeutics Ltd 주식(NRSN)의 최신 뉴스
Why Is NeuroSense (NASDAQ:NRSN) in Focus Before Tuesday’s Open? - Kalkine Media
Amyotrophic Lateral Sclerosis Pipeline 2026: FDA Approvals, - openPR.com
NRSN Q2'26 Earnings: EPS estimate is (0.20) USD - TradingView
NeuroSense Unveils Accelerated, Capital-Efficient Strategy to Advance PrimeC Toward Potential Approval in ALS - Morningstar
NeuroSense Rewrites the Standard ALS Playbook With a Faster, Leaner Path to Potential Approval - TipRanks
NeuroSense Therapeutics Ltd. Warrant (NRSNW) Peer Comparison – Compare with Others - valueresearchonline.com
NeuroSense Therapeutics Ltd. Revenue Breakdown – NASDAQ:NRSN - TradingView
12 Health Care Stocks Moving In Tuesday's After-Market Session - Sahm
NeuroSense (NRSN) Snapshot: Finishes 7.39% Higher at $0.38 in the Latest Reading; Next Session - vinanet.vn
Neurosense Therapeutics Stock Price Forecast. Should You Buy NRSN? - StockInvest.us
NeuroSense CEO Details Phase 3 ALS Trial Plans, Canada Filing and Nasdaq Compliance Efforts - The Globe and Mail
Amyotrophic Lateral Sclerosis Pipeline Shows Strong Momentum as 80+ Pharma Companies in the Race | DelveInsight - openPR.com
NeuroSense Issues CEO Letter to Shareholders - Nasdaq
NeuroSense Therapeutics (NRSN) Slips to $0.47 as Bulls Defend Key Support FloorNHNL Ratio - dars.gov.et
Global Neurodegenerative Disease Market is Expected to - GlobeNewswire
NeuroSense Therapeutics (NRSN) Dips 1.6% to $0.49, Testing Key Support at $0.47PCR Moving Average - dars.gov.et
NeuroSense Advances PrimeC Toward December 2026 Health Canada Filing After Completing Pre-NDS Process - TipRanks
NeuroSense Completes PrimeC Pre-NDS Process and Advances Toward December 2026 Filing with Health Canada - GuruFocus
Health Canada review path for PrimeC: NeuroSense (NASDAQ: NRSN) - Stock Titan
NeuroSense Therapeutics (NRSN) Jumps 11.35% to $0.52, Nears Key Resistance at $0.55Weekly Profile - dars.gov.et
CNSY Stock Price and Chart — NASDAQ:CNSY - tradingview.com
NeuroSense Therapeutics Ltd. SEC Filing (Aug 3, 2026) - Stock Titan
NeuroSense Therapeutics Calls August 26 Shareholder Vote on Wide-Range Reverse Share Split - TipRanks
NeuroSense Therapeutics (NRSN) seeks reverse split amid Nasdaq compliance push - Stock Titan
NeuroSense Updates Capital on Demand Program After New F-3 Becomes Effective - TipRanks
NeuroSense Therapeutics (NRSN) sets $150M shelf and $3.8M ATM share plan - Stock Titan
NeuroSense Therapeutics (NRSN) Plunges 14% – Testing Critical Support at $0.46Sentiment Shift - vinanet.vn
Neurosense Therapeutics is a buy, this analyst says - Cantech Letter
Neurosense Therapeutics Ltd expected to post breakeven results a shareEarnings Preview - TradingView
Neurosense Therapeutics Ltd. Revenue Breakdown – FWB:H1Z - TradingView
Neurosense Therapeutics Ltd - TradingKey
Neurosense Therapeutics Ltd (NRSN) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Neurosense Therapeutics Ltd (NRSN) Cash Flow - TradingKey
NRSN|Neurosense Therapeutics Ltd|Price:0.602|Chg%:-0.048 - TradingKey
Neurosense Therapeutics Ltd (NRSN) Valuation: PE, PB & Fair Value Analysis - TradingKey
NRSN|Neurosense Therapeutics Ltd|Price:0.511|Chg%:+0.109 - TradingKey
TradingKey - TradingKey
NeuroSense Therapeutics (NRSN) Gains 3.08% as Stock Tests Key Resistance at $0.70Upthrust Pattern - vinanet.vn
NeuroSense Moves PrimeC Toward Health Canada Drug Submission for ALS - TipRanks
NeuroSense Therapeutics (NASDAQ: NRSN) eyes Canada NDS for ALS drug - Stock Titan
NeuroSense Advances PrimeC Toward New Drug Submission to Health Canada for ALS - PR Newswire
NRSN Q2 2025 Earnings: Narrower-than-Expected Loss Fails to Soothe ShareholdersHealthcare Earnings Report - vinanet.vn
NeuroSense Therapeutics (NRSN) Faces Headwinds: Stock Retreats 5.6% to $0.69 Amid Sector PressureMarket Profile - vinanet.vn
NeuroSense Therapeutics (NRSN) Slips 2.6% as Stock Tests Key Support at $0.65Cumulative Volume - vinanet.vn
NeuroSense Therapeutics (NRSN) Slides 2.3% as Sellers Test Key Support at $0.66Calendar Spread Trade - dars.gov.et
NeuroSense Therapeutics (NRSN) Edges Higher as Key Support HoldsEquity Put Call - dars.gov.et
NeuroSense Therapeutics Ltd. (NRSN) Latest Stock News & Headlines - Yahoo Finance
NeuroSense to Participate in Roth-Hosted KOL Webinar on the Future of ALS Treatment: "A Quest to Outrun ALS" - Nasdaq
Enterprise value to revenue forward of NeuroSense Therapeutics Ltd. – NASDAQ:NRSN - TradingView
Price to earnings forward of NeuroSense Therapeutics Ltd. – NASDAQ:NRSN - TradingView
NeuroSense Therapeutics Ltd. Warrant 2021-open end Financial Disclosures & SEC Filings - TradingView
NeuroSense bolsters case for multi-target Alzheimer’s strategy - Longevity.Technology
NRSN Q2 2025 Earnings: Narrower-Than-Expected Loss Highlights Cost DisciplineBasic EPS Analysis - dars.gov.et
NeuroDex ExoSORT Platform Demonstrates Treatment-Responsive Blood-Based Measurement of Neuronal TDP-43 in People Living with ALS - Bakersfield.com
NeuroSense (NRSN) Achieves Key Milestone in ALS Study - GuruFocus
NeuroSense Hits Key TDP-43 Endpoint in Phase 2b ALS Trial, Advances Toward Phase 3 - TipRanks
NeuroSense Says Phase 2b Trial of PrimeC in Amyotrophic Lateral Sclerosis Meets Primary Endpoint - marketscreener.com
NeuroSense (NRSN) Phase 2b ALS study cuts TDP-43, eyes Phase 3 - Stock Titan
NeuroSense Achieves Primary Endpoint in Phase 2b ALS Study with Statistically Significant Reduction of TDP-43, the Defining Pathological Hallmark of ALS - Nasdaq
NeuroSense reports positive Phase 2b ALS data - grafa.com
NeuroSense reports Phase 2 biomarker findings for PrimeC in Alzheimer’s disease - BioSpectrum Asia
0.86%
0.31%
자본화:
|
볼륨(24시간):